Feasibility of convection-enhanced delivery of unlabeled

Maram El Sabri, Leyla Moghaddasi, Puthenparampil Wilson, Frank Saran, Eva Bezak

Abstract read

In one paragraph

Article in Medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maram El SabriCollege of Health, School of Allied Health and Human Performance, Adelaide University, Adelaide, South Australia, Australia.

Leyla MoghaddasiDepartment of Medical Physics, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Puthenparampil WilsonCollege of Science, School of Physics, Chemistry and Earth Sciences, Adelaide University, South Australia, Australia.

Frank SaranCollege of Health, School of Allied Health and Human Performance, Adelaide University, Adelaide, South Australia, Australia.

Eva BezakCollege of Health, School of Allied Health and Human Performance, Adelaide University, Adelaide, South Australia, Australia.

Funding

Australian Government Research Training Program Scholarship

6 · The paper itself

Abstract

backgroundGlioblastoma (GB) is an aggressive primary brain tumor with local recurrence rates exceeding 90% and a five-year survival rate of approximately 5%. Standard treatments such as surgical resection, external beam radiotherapy (EBRT), and chemotherapy often leave residual tumor cells that are resistant to therapy. Local targeted alpha therapy (TAT) with actinium-225 ( PURPOSE: This study presents a computational model simulating the distribution of unlabeled

methodsA Python-based CED model was developed incorporating diffusion (diffusion coefficient = 1.0 × 10

resultsCED achieved therapeutic doses (≥ 2 Gy (RBE)/ MBq) to ∼1.43 cm from injection sites. A five-injection plan delivering a total of 10 MBq reduced the global survival fraction (SF) from 100% (no alpha therapy) to ∼3.4%, with further reductions to ∼2.0% and ∼1.4% at 20 MBq and 30 MBq, respectively. Residual clonogenic tumor cells were mainly located > 2 cm from injection sites. Sensitivity analysis identified injection site placement and total activity as the dominant efficacy factors, whereas varying the RBE had minimal effect. Early tumor repopulation (T

conclusionsThis study supports the feasibility of CED of

Indexed as

ActiniumBrain NeoplasmsConvectionGlioblastomaModels, BiologicalBiological TransportCell SurvivalFeasibility StudiesHumansRadiometryActiniumActinium-225alpha therapycomputational modelingconvection‐enhanced deliveryglioblastomaMonte‐Carlo simulationradionuclide therapy

Identifiers

PMID42482373

DOI10.1002/mp.70566

PMCPMC13389104

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.